Capital Fund Management S.A. Acquires 21,762 Shares of Biohaven Ltd. (NYSE:BHVN)

Capital Fund Management S.A. grew its stake in Biohaven Ltd. (NYSE:BHVN) by 130.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 38,488 shares of the company’s stock after purchasing an additional 21,762 shares during the period. Capital Fund Management S.A.’s holdings in Biohaven were worth $1,438,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. grew its position in Biohaven by 8.1% in the fourth quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company’s stock valued at $314,267,000 after acquiring an additional 628,211 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Biohaven by 144.5% in the 4th quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company’s stock valued at $73,922,000 after purchasing an additional 1,169,721 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Biohaven by 11.1% in the 4th quarter. Geode Capital Management LLC now owns 1,905,366 shares of the company’s stock worth $71,182,000 after purchasing an additional 190,754 shares during the last quarter. ARS Investment Partners LLC increased its position in shares of Biohaven by 1.0% during the 4th quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company’s stock worth $38,871,000 after purchasing an additional 10,473 shares in the last quarter. Finally, Norges Bank bought a new position in Biohaven during the 4th quarter valued at about $33,711,000. 88.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BHVN shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a report on Tuesday, December 17th. Morgan Stanley cut their price objective on Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. JPMorgan Chase & Co. decreased their target price on Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the company a “buy” rating in a research note on Thursday, March 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Fourteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Biohaven currently has an average rating of “Buy” and a consensus target price of $62.77.

Biohaven Stock Performance

Shares of Biohaven stock opened at $18.56 on Wednesday. Biohaven Ltd. has a 52 week low of $15.79 and a 52 week high of $55.70. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of -1.99 and a beta of 1.33. The firm has a fifty day moving average of $29.63 and a two-hundred day moving average of $39.12.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). As a group, research analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Insider Activity at Biohaven

In other Biohaven news, Director John W. Childs acquired 32,700 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average price of $30.47 per share, with a total value of $996,369.00. Following the purchase, the director now owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. This represents a 1.43 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 16.00% of the stock is currently owned by corporate insiders.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.